Patients with alopecia areata who did not respond to initial treatment with a JAKi or who did not maintain response may ...

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on ...

Researchers have found in a multicentre real-world study that ritlecitinib 50 mg/day was found to be an effective and ...

FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly announced on Friday safety ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor under investigation for the treatment of multiple dermatologic indications ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

Claims-based MarketScan analyses (>11,000 patients) showed moderate-to-severe alopecia areata carried higher atopic dermatitis risk than mild disease (adjusted HR 1.8; 95% CI 1.1–2.8). Baseline atopic ...

TORONTO, Jan. 14, 2026 /CNW/ - Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant ® for severe alopecia areata to its public drug ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Baricitinib maintained hair regrowth among adolescents ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.